Rifabutin for Eradicating Helicobacter pylori?

In a trial in China involving patients who had previously failed treatment, rifabutin triple therapy had an H. pylori eradication rate similar to bismuth quadruple therapy, but with fewer adverse events.

Likelihood of failure to eradicate Helicobacter pylori after one or more treatments is on the rise, particularly because of clarithromycin resistance. Accordingly, rescue regimens — including quadruple therapy containing bismuth — have been recommended. As these have been associated with adverse events, an alternative approach is combination therapy with rifabutin, which is highly active against H. pylori. Researchers in China performed an open label noninferiority study in 364 patients who had failed at least two prior treatments. Participants were randomized to 14 days of bismuth quadruple therapy (bismuth, esomeprazole, metronidazole, and tetracycline) or rifabutin triple therapy (rifabutin, esomeprazole, and amoxicillin).

In the intentio…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Rifabutin for Eradicating Helicobacter pylori?

Topics

Reviewing Author